Liposomal amphotericin B (AmBisome<sup>®</sup>) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis
MycosesPublished 22 March 2007
Catherine Cordonnier, Mark Bresnik, Ramin Ebrahimi
Citations28
SJR quartileQ1
SJR score0.93
SNIP1.30
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The response rates observed in this analysis were consistent with previous reports for antifungal therapy with amphotericin B deoxycholate or voriconazole in the treatment of invasive aspergillosis.
Abstract
A pooled efficacy analysis applying current diagnostic standards for case selection was performed on previously published trials of liposomal amphotericin B for invasive filamentous fungal infections (IFFI). Favourable responses were observed in 51% of microbiologically confirmed cases of proven or probable IFFI. Despite the limitations inherent in a retrospective analysis of pooled studies, the response rates observed in this analysis were consistent with previous reports for antifungal therapy with amphotericin B deoxycholate or voriconazole in the treatment of invasive aspergillosis.
Keywords
Medicine
New England Journal of MedicineVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
3,297 Citations2002Raoul Herbrecht, David W. Denning +20 more
In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.
Clinical Infectious DiseasesDefining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
2,338 Citations2002S. Ascioglu, John Rex +18 more
A set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed and three levels of probability are proposed: "proven," "probable," and "possible."
New England Journal of MedicineLiposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
1,195 Citations1999Thomas J. Walsh, Robert W. Finberg +11 more
Liposomal amphotericin B is as effective as conventional amphoteric in B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal infections, less infusion-related toxicity, and less nephrotoxicity.
Clinical Infectious DiseasesEfficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis
848 Citations2002David W. Denning, Patricia Ribaud +7 more
Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients.
Clinical Infectious DiseasesEfficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy
656 Citations2004J. Maertens, Issam Raad +12 more
Caspofungin demonstrated usefulness in the salvage treatment of IA and was observed in 37 (45%) of 83 patients, including 32 (50%) of 64 with pulmonary aspergillosis and 3 (23%) of 13 with disseminated asperGillosis.
Journal of Antimicrobial ChemotherapyAmphotericin B: spectrum and resistance
466 Citations2002David Ellis
Of the 200 known polyene agents, amphotericin B is the only one with toxicities that are sufficiently limited to permit intravenous administration, and has a relatively broad spectrum of action and is useful in treating cases of candidosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomyCosis, coccidioidsomycotic, extracutaneous sporotrichosis and mucormycosis.
Antimicrobial Agents and ChemotherapySafety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with<i>Aspergillus</i>Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
401 Citations2001Thomas J. Walsh, Jesse L. Goodman +6 more
The findings indicate that L-AMB at dosages as high as 15 mg/kg/day follows nonlinear saturation-like kinetics, is well tolerated, and can provide effective therapy for aspergillosis and other filamentous fungal infections.
Transplant Infectious DiseaseThe incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants
351 Citations2002A. Minari, Rola Husni +9 more
The highest incidence and attack rate of invasive aspergillosis among solid organ transplant recipients occurs in lung transplant recipients and supports the routine use of Aspergillus prophylaxis for at least one year after transplantation in this group.
British Journal of HaematologyLiposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections
321 Citations1998Alexander C. A. P. Leenders, Simon Daenen +10 more
A randomized multicentre study comparing liposomal amphotericin B (AmBisome, 5 mg/kg/d) to amphoteric in B deoxycholate (Am b) in the treatment of neutropenia‐associated invasive fungal infections, finding a favourable trend at day 14 and lower mortality rates in patients with documented infections.
Journal of Antimicrobial ChemotherapyEfficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
281 Citations1991Olle Ringdén, F. Meunier +10 more
It is concluded that AmBisome is an effective antifungal agent in a majority of patients with invasive or superficial fungal infections.
Clinical Infectious DiseasesAn EORTC International Multicenter Randomized Trial (EORTC Number 19923) Comparing Two Dosages of Liposomal Amphotericin B for Treatment of Invasive Aspergillosis
254 Citations1998Michael Ellis, David J. Spence +13 more
This is the first completed prospective randomized clinical efficacy trial of antifungals in the treatment of invasive aspergillosis (IA) and the first to compare the clinical efficacy of two dosages of liposomal amphotericin B (L-AmB) for IA in neutropenic patients with cancer or those undergoing bone marrow transplantation.
British Journal of HaematologyLiposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single‐centre experience of 133 episodes in 116 patients
172 Citations1994Wendy Mills, Rajesh Chopra +2 more
AmBisome is well tolerated and effective against invasive mycoses in neutropenic patients, and may salvage patients when conventional amphotericin proves excessively toxic or ineffective, as well as evaluable in those with proven aspergillosis.
Archives of Internal MedicineLiposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections
132 Citations1995Tony Ng
AmBisome is efficacious in the treatment of invasive fungal infections and provides an alternative therapy for those who fail to respond or become intolerant to conventional amphotericin B therapy.
BloodLiposomal Amphotericin B (L-AMB) as Initial Therapy for Invasive Filamentous Fungal Infections (IFFI): A Randomized, Prospective Trial of a High Loading Regimen vs. Standard Dosing (AmBiLoad Trial).
33 Citations2005Oliver A. Cornely, Johan Maertens +2 more
In a population of highly immunocompromised patients (93% with underlying hematological malignancies, 73% with neutropenia at study entry), L-AMB as initial treatment of invasive aspergillosis and other filamentous fungal infections at a standard dose of 3 mg/kg/d had an overall favorable response rate and a 12 wk survival rate of 72%.
Clinical Drug InvestigationEarly Pharmacokinetic and Clinical Results from a Noncomparative Multicentre Trial of Amphotericin B Encapsulated in a Small Unilamellar Liposome (AmBisome®)
25 Citations1992J Tollemar, Olle Ringdén
AmBisome® 0.5 to 4 mg/kg/day, a small unilamellar liposome encapsulating amphotericin B, was administered to 59 patients with ideologically confirmed infections and 80% of 20 evaluable patients were cured or improved when AmBISome® was used because of the prior failure of conventional amphoteric in B in a compassionate basis trial.
Archives of Internal MedicineLiposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data
23 Citations1995T. T. Ng
BloodA Novel, Efficacious Therapeutic Approach to Patients with Acute Promyelocytic Leukemia (APL) Using Differentiating Agent and Metronomic Chemotherapy (CT).
10 Citations2005Shripad Banavali, Lovenish Goyal +11 more
There is a valuable role of single hospital trials in exploring innovative therapies in APL and the protocol was well tolerated on out-patient basis and after the initial admission at presentation, only 6 patients required readmission.